Extracorporeal life support for adults with malignancy and respiratory or cardiac failure: The Extracorporeal Life Support experience
Related Experiment Video
Updated: Jun 13, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
Published on: January 17, 2025
Kenneth W Gow1, Oliver B Lao, Traci Leong
1Department of Surgery, University of Washington, Seattle, WA, USA. kenneth.gow@seattlechildrens.org
Background:
Adults with cancer may be considered for extracorporeal life support (ECLS) as a means of support if failing conventional therapy.
Methods:
The Extracorporeal Life Support Organization Registry was queried for patients aged >or=21 years with diagnoses of malignancy or hematopoietic stem cell transplantation.
Results:
Seventy-two adults met inclusion criteria: 47 with solid tumors, 21 with hematologic malignancies, and 4 with hematopoietic stem cell transplantation. Patients required ECLS primarily for pulmonary support (n = 54). The median duration of ECLS was 4.1 days. Overall, 44 patients (61%) died on ECLS, 23 (32%) survived to hospital discharge, and 5 (7%) survived ECLS but died before discharge. Risk factors for death include pulmonary support as reason for ECLS, impaired lung function before ECLS, and development of infection.
Conclusions:
Adults with cancer can be offered ECLS with a small but real expectation for survival. Impaired pulmonary status and the development of infections are associated with death.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Cardiopulmonary Resuscitation I: Adult
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cardiopulmonary Resuscitation II: ACLS Airway Management
